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New Breast Cancer Treatment
Using chemotherapy and hormonal thera-
p es to treat breast cancer has been success-
ful, but preventing the cancer from return-
ing continues to be a major problem.
Researchers at Duke University have devel-
oped a unique way ofusing immunothera-
py to tackle this problem.
The treatment, developed by a team
led by Kim Lyerly, co-director of Duke's
Center for Molecular Therapeutics,
involves the injection of a patient's own
tumor cells that have been genetically
modified into the body to activate extra
immune cells that would stop or slow the
growth oftumors. Preliminary tests on ani-
mals have been successful, and the Duke
researchers hope to begin tests soon on
women with breast cancer.
Lyerly said the idea for the treatment
stemmed from observations that mice with
cancer could be immunized to fight offtheir
cancers. The researchers found that mice
with breast cancer responded when injected
with their own modified immune cells.
Lyerly conducted experiments in which
he removed cancer cells from mice and
altered the genetic material within each
cell. The cells, which were reinserted into
the mice, were engineered to secrete inter-
leukin 2, one of the body's natural
immune system boosters. After the treat-
ment, the lungs ofthe mice were weighed
and the tumor nodules were counted.
According to Lyerly, there was a significant
reduction in the number oftumor nodules
and the weight of the lungs of treated
mice, as compared to the control mice.
Lyerly said the treatment is not meant
to cure breast cancer, but rather to work
with current forms oftreatment to prevent
the cancer from returning. According to
the American Cancer Society, there are
182,000 cases of breast cancer nationwide
each year, and 46,000 deaths each year are
attributed to breast cancer. The rate of
recurrence following current forms of
treatment depends on the type ofcancer.
The Duke research team has received
approval from the National Institutes of
Health to test the treatment on women
with advanced breast cancer. Preliminary
tests will determine whether the treatment
is safe. Lyerly said that one possible prob-
lem with the treatment is that it could
induce autoimmunity against undiseased
parts ofthe body.
Lyerly and co-workers are nowworking
to submit an application to the FDA,
which usually approves or disapproves of
an application within a month. Lyerly said
the team is working quickly to submit the
application, but some safety issues still
have to be resolved. The researchers will
begin tests as soon as possible if the FDA
approves the experiment. Lyerly said the
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The body's own ammunition. Genetically modified tumor cells may activate the body's immune system to
stop or slowthe growth oftumors.
tests will be conducted on women who
have failed to respond to other forms of
treatment. The women would receive der-
mal injections of their own treated cells
approximately four separate times.
Based on the original tests, the
researchers caution that they do not expect
a tremendous response. "We don't think
we'll see much, but we can test for induc-
tion of immunity," Lyerly said. "And we
want to make sure that it's safe."
No Agreement on
Environmental Justice
A mandate by the federal government that
agencies incorporate environmental justice
into their decision-making has been
applauded by environmental justice advo-
cates. However, it seems that agreement as
to how this should be done is far from
being settled. A first attempt by the
Nuclear Regulatory Commission prompt-
ed controversy among all parties involved.
Last year, the NRC attempted to
address environmental justice in an envi-
ronmental impact statement (EIS) pre-
pared for the construction ofthe Claiborne
Enrichment Center in Homer, Louisiana.
The proposed site is located between two
predominately African-American commu-
nities. The NRC and the EPA, the agency
responsible for reviewing the EIS under the
National Environmental Policy Act, drew
intense criticism from environmental jus-
tice advocates, who charged the EPA with
setting a dangerous precedent for future
reviews.
The EPA Region VI in Dallas, Texas,
reviewed the first draft ofthe EIS inJanuary
1994, saying, "based on the type ofproject
and the location ofthe preferred site, we are
concerned that your draft EIS did not
specifically address the issue of 'environ-
mental justice."' Several public comments
on the draft alleged that the site was chosen
because itwas a minoritycommunity.
A few weeks after EPA's review,
President Clinton signed the executive
order on environmental justice, which
directs federal agencies to analyze, "the
environmental effects, including human
health, economic and social effects, offed-
eral actions." In response to the executive
order and EPA's comments, the NRC
added a section in the final August EIS to
cover the issue of environmental justice
which states: "[NRC] staff recognizes that
to the extent the CEC affects the environ-
ment, those living closest will be the most
affected. All aspects ofCEC operation will
be required to comply with State and
Federal environmental regulations ... staff
found no evidence of racial considerations
being used in the site selection process, and
the staffdoes not believe that facility oper-
ation will result in significantly dispropor-
tionate adverse impact."
The EPA Region VI responded to the
NRC's addition in a letter on 25 October
1994, saying, "Although the final EIS does
contain a section on [environmental jus-
tice], we fail to find any specific analysis
supporting the NRC's conclusion "that the
facility is not an example of" environmen-
tal injustice. The EPA pointed out that the
NRC staff failed to weigh the cumulative
impacts of the facility and other polluting
industries near the community, and that
while the NRC staff examined race and
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